biostudies-literatureUnknown12(2)Bogelund M<h4>Background</h4>This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy-tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective.<h4>Methods</h4>A discrete choice experiment (DCE) consisting of two blocks with eight choice sets in each was constructed to elicit the preferences for AIT. Three attributes were included in the DCE for the mode of administration, including the frequency of administration, the risk of systemic reactions and the co-payment. Adults and caregivers of children with moderate to severe allergic rhinitis (AR) were included if they were not currently receiving or had not previously received AIT.<h4>Results</h4>In total, 587 adults and 613 caregivers startClinical and translational allergye12118https://www.ebi.ac.uk/biostudies/studies/S-EPMC8814907biostudies-literaturePreference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis.PMC8814907Loftager ASLPedersen MHIngelmo ARAagren MVivo AGBrandi HBogelund MRuiz JMAfalsePreference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis.<h4>Background</h4>This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy-tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective.<h4>Methods</h4>A discrete choice experiment (DCE) consisting of two blocks with eight choice sets in each was constructed to elicit the preferences for AIT. Three attributes were included in the DCE for the mode of administration, including the frequency of administration, the risk of systemic reactions and the co-payment. Adults and caregivers of children with moderate to severe allergic rhinitis (AR) were included if they were not currently receiving or had not previously received AIT.<h4>Results</h4>In total, 587 adults and 613 caregivers start2022-01-01T00:00:00Z2022 Feb2025-04-22T04:53:49.556Z2025-04-05T21:04:27.406ZS-EPMC88149073514091010.1002/clt2.12118